Document Detail

Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
MedLine Citation:
PMID:  20485161     Owner:  NLM     Status:  In-Process    
PURPOSE OF REVIEW: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor as strong as low-density lipoprotein (LDL) cholesterol. Therapies targeting Lp-PLA2 in plasma and plaque are now being developed. This article will review these data.
RECENT FINDINGS: Lp-PLA2 is intimately involved in the development of atherosclerosis and is found in vulnerable human plaques. Multiple epidemiological studies have shown that Lp-PLA2 is related to the occurrence of myocardial infarction (MI), stroke and vascular death.Darapladib is a novel oral compound that selectively inhibits Lp-PLA2 in plasma and in human plaques. Darapladib has also been shown to halt necrotic core progression in coronary arteries over a 12-month period and to have few adverse effects.
SUMMARY: Two large phase III trials are randomizing 26,000 patients to darapladib or placebo with chronic coronary heart disease or following an acute coronary syndrome. The primary composite outcomes are cardiovascular death, MI or stroke and results should be available in 2012. Darapladib has the potential to improve patient outcomes in addition to evidence-based treatments by modulating mechanisms of disease that have not been addressed by current therapies.
Harvey White
Publication Detail:
Type:  Editorial; Review    
Journal Detail:
Title:  Current opinion in cardiology     Volume:  25     ISSN:  1531-7080     ISO Abbreviation:  Curr. Opin. Cardiol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8608087     Medline TA:  Curr Opin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  299-301     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patch testing in drug allergy.
Next Document:  Blood pressure targets: are clinical guidelines wrong?